FDA OKs lecanemab Under Accelerated Approval for Treatment of Alzheimer's

 Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials

https://finance.yahoo.com/news/fda-approves-leqembi-lecanemab-irmb-193000095.html